INmune Bio, Inc. (INMB) Earnings History
Net Loss11 years of earnings data (2015–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
INmune Bio, Inc. (INMB) Earnings Overview
As of June 22, 2026, INmune Bio, Inc. (INMB) reported trailing twelve-month net income of -$42M, reflecting +11.8% year-over-year growth. The company earned $-1.56 per diluted share over the past four quarters, with a net profit margin of -91866.0%.
Looking at the long-term picture, INMB's historical earnings data spans multiple years. The company achieved its highest annual net income of -$48,868 in fiscal 2015.
INmune Bio, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SAVA (-$106M net income), PRTA (-$151M net income, -2520.6% margin), ACAD ($376M net income, 36.5% margin), INMB has comparable earnings metrics. Compare INMB vs SAVA →
INMB Earnings vs Peers
Earnings metrics vs comparable public companies
INMB Historical Earnings Data (2015–2025)
11 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$46M | -9.2% | -$31M | $-1.86 | -91866.0% | -61738.0% |
| 2024 | -$42M | -40.2% | -$43M | $-2.11 | -300585.7% | -304535.7% |
| 2023 | -$30M | -9.9% | -$30M | $-1.67 | -19360.0% | -19187.7% |
| 2022 | -$27M | +10.0% | -$26M | $-1.52 | -7299.2% | -6938.8% |
| 2021 | -$30M | -150.8% | -$29M | $-1.88 | -16762.4% | -16106.6% |
| 2020 | -$12M | -57.6% | -$12M | $-1.01 | -109990.9% | -111163.6% |
| 2019 | -$8M | +38.3% | -$8M | $-0.89 | - | - |
| 2018 | -$12M | -1397.0% | -$12M | $-1.11 | - | - |
| 2017 | $-831,000 | -200.0% | $-981,000 | $-0.07 | - | - |
| 2016 | $-277,000 | -466.8% | $-227,000 | $-0.05 | - | - |
| 2015 | $-48,868 | - | $-48,868 | $-0.01 | - | - |
Download Data
Export INMB earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
11+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
INMB — Frequently Asked Questions
Quick answers to the most common questions about buying INMB stock.
What is INMB earnings per share (EPS)?
INMB trailing twelve-month (TTM) diluted EPS is $-1.56, reflecting +11.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2015 to 2025 is available in the table on this page.
What is INmune Bio, Inc.'s net income?
INmune Bio, Inc. (INMB) trailing twelve-month net income is $-42M as of 2025. Earnings grew +11.8% year-over-year.
Is INMB profitable?
INMB is not currently profitable on a TTM basis, reporting a net loss of $-42M. Net margin is -91866.0%. Investors should monitor for a return to profitability.
What is INMB's earnings growth rate?
INMB compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2015 to 2025.
What are INMB's profit margins?
INmune Bio, Inc. net profit margin is -91866.0%, operating margin is -61738.0%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -165.2%.
Is INMB growing earnings?
INMB is growing earnings steadily. YoY EPS growth of +11.8% is consistent with the 5-year CAGR of N/A. TTM net income is $-42M.
What was INMB's best earnings year?
INmune Bio, Inc.'s highest annual net income on record is $-48868.00, achieved in fiscal year 2015. Earnings history on this page spans 2015 to 2025 and includes all annual and quarterly figures.
What were INMB's earnings last quarter?
INMB's most recent reported quarter was Q1 2026. Net income was $-5M with diluted EPS of $-0.20. For a full breakdown of all quarters, see the quarterly earnings table on this page.